[ad_1]
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into NRx Pharmaceuticals (NASDAQGM:NRXP).
In June 2021, the Company announced that it filed an application with US Food and Drug Administration (“FDA”) requesting Emergency Use Authorization (“EUA”) for Zyesami, its investigational pre-commercial drug product for treating COVID-19 related respiratory failure . Then, on November 4, 2021, the Company disclosed that the FDA had declined to issue an EUA for Zyesami “due to insufficient data regarding the known and potential benefits of …
Full story available on Benzinga.com
[ad_2]
Source link
